Role of transcription termination factor Rho in anti-tuberculosis drug discovery.

Sunil Kumar, Shashikanta Sau, Puja Kumari Agnivesh, Arnab Roy, Nitin Pal Kalia

Drug discovery today 2023 Mar

filter terms:

Mycobacterial infections, including multidrug and extreme drug-resistant (MDR and XDR) infections, are a severe challenge and create a virtual antibiotic-deficient era. Bacterial transcription is an established antimicrobial drug target. In mycobacteria, efficient transcription termination relies on the ATP-dependent RNA helicase factor Rho. Rho factor is essential for Mycobacterium tuberculosis (Mtb) survival, and is a valid antibacterial drug target with no homolog in eukaryotes. Rho maintains genomic stability and virulence and prevents pervasive transcription in Mtb. In this review, we provide an overview of the essentiality of Rho in Mtb, which makes it an attractive drug target for inhibitor discovery. Copyright © 2023 Elsevier Ltd. All rights reserved.

Citation

Sunil Kumar, Shashikanta Sau, Puja Kumari Agnivesh, Arnab Roy, Nitin Pal Kalia. Role of transcription termination factor Rho in anti-tuberculosis drug discovery. Drug discovery today. 2023 Mar;28(3):103490